| EEG abnormalities during treatment with tadalafil, a phosphodiesterase type 5 inhibitor. | |
| | |
MedLine Citation:
|
PMID: 19036180 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: Tadalafil is a selective phosphodiesterase type 5 (PDE-5) inhibitor approved for the treatment of erectile dysfunction. Less is known about the electroencephalography (EEG) effects of PDE-5 inhibitors, and the present study, therefore, examined the risk of EEG abnormalities associated with tadalafil. METHOD: EEG recordings from 35 erectile dysfunction patients taking tadalafil (20 mg) were graded for severity of EEG abnormalities (at admission, 2 and 48 hours after tadalafil administration). RESULTS: At admission, there were no EEG abnormalities. At second EEG, abnormalities occurred in 12 (34.3%) of the 35 patients. Eight (22.9%) patients had mild and four (11.4%) patients had moderate EEG abnormalities. At third EEG, one (2.9%) patient had mild and one (2.9%) patient had moderate EEG abnormalities. CONCLUSION: PDE-5 inhibitors may produce EEG abnormalities. Although the exact role of PDE in altering susceptibility to seizure remains unclear, epileptic seizures may occur during treatment with PDE inhibitors. |
| | |
Authors:
|
Esra E Okuyucu; Oguz Guven; Taskin Duman; Sadik Gorur; Ismet M Melek; Soner Akcin; Serkan Yilmazer |
Publication Detail:
|
Type: Journal Article Date: 2008-11-25 |
Journal Detail:
|
Title: Neurological research Volume: 31 ISSN: 0161-6412 ISO Abbreviation: Neurol. Res. Publication Date: 2009 Apr |
Date Detail:
|
Created Date: 2009-05-01 Completed Date: 2009-07-07 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7905298 Medline TA: Neurol Res Country: England |
Other Details:
|
Languages: eng Pagination: 313-5 Citation Subset: IM |
Affiliation:
|
Department of Neurology, Mustafa Kemal University, Antakya, Turkey. esraokuyucu@yahoo.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Carbolines
/
adverse effects*,
therapeutic use Cohort Studies Cyclic Nucleotide Phosphodiesterases, Type 5 / antagonists & inhibitors* Electroencephalography / drug effects* Erectile Dysfunction / drug therapy* Humans Male Middle Aged Phosphodiesterase Inhibitors / adverse effects*, therapeutic use Time Factors |
| Chemical | |
Reg. No./Substance:
|
0/Carbolines; 0/Phosphodiesterase Inhibitors; 0/tadalafil; EC 3.1.4.35/Cyclic Nucleotide Phosphodiesterases, Type 5 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Differential expression of HSP70 mRNA in the mouse brain after treatment with geldanamycin.
Next Document: Behavioral model for Homalodisca vitripennis (Hemiptera: Cicadellidae): optimization of host plant u...